Organization
University of Occupational and Environmental Health, Kitakyushu, Japan
18 abstracts
Abstract
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,
Abstract
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.Org: Dana-Farber Cancer Institute, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Bristol Myers Squibb, Institut Curie, Saint Cloud, France, McGill University Health Center,
Abstract
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.Org: Juntendo University School of Medicine, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Hiroshima University, National Cancer Center Hospital Japan East, Kashiwa, Japan, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Real-world efficacy of chemotherapy in patients with advanced extramammary Paget's disease: A retrospective, multicenter study of 204 Japanese patients.Org: Kumamoto University Hospital, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Nagoya City University Graduate School of Medical Sciences, National Cancer Center Hospital East, Kashiwa, Japan, Graduate School of Medicine, Chiba University,
Abstract
14-3-3ETA PREDICTS JOINT DAMAGE PROGRESSION AND FLARING AFTER ADALIMUMAB DISCONTINUATION Org: Hiroshima University Hospital, University of Occupational and Environmental Health, Kitakyushu, Japan, Augurex Life Sciences Corp, North Vancouver, Canada,
Abstract
A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEFICITINIB (ASP015K) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO METHOTREXATEOrg: Keio University, Tokyo, Japan, University of Occupational and Environmental Health, Kitakyushu, Japan, University of Tokyo, Tokyo, Japan, Nagasaki University, Nagasaki, Japan, Yokohama City University, Yokohama, Japan,
Abstract
A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARSOrg: University of Occupational and Environmental Health, Kitakyushu, Japan, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Rep. of (South Korea), GlaxoSmithKline, Collegeville, United States of America, GlaxoSmithKline (at the time of the study), Collegeville, United States of America, GlaxoSmithKline, Uxbridge, United Kingdom,
Abstract
Autoantibody profiling for response to baricitinib in patients with rheumatoid arthritis and no or limited exposure to methotrexateOrg: Charité-Universitätsmedizin Berlin, Orgentec Diagnostika Gmbh, Mainz, Eli Lilly and Company, University of Occupational and Environmental Health, Kitakyushu, Japan,
Abstract
A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEFICITINIB (ASP015K) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO DMARDSOrg: University of Occupational and Environmental Health, Kitakyushu, Japan, Keio University, Tokyo, Japan, University of Tokyo, Tokyo, Japan, Nagasaki University, Nagasaki, Japan, Yokohama City University, Yokohama, Japan,
Abstract
A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF TAS5315—A NOVEL HIGHLY SELECTIVE INHIBITOR OF BRUTON’S TYROSINE KINASE—IN HEALTHY MALE VOLUNTEERSOrg: Kitasato University School of Medicine, Kanagawa, Japan, University of Occupational and Environmental Health, Kitakyushu, Japan, Keio University School of Medicine, Keio University School of Medicine, Japan,
Abstract
52-WEEK RESULTS OF CLINICAL, RADIOGRAPHIC AND PHARMACOKINETIC ASSESSMENTS: GOLIMUMAB, A HUMAN ANTI-TNF MONOCLONAL ANTIBODY, ADMINISTERED SUBCUTANEOUSLY EVERY FOUR WEEKS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY Org: University of Occupational and Environmental Health, Kitakyushu, Japan, Tokyo Medical and Dental University, Keio University School of Medicine, Tokyo Women's Medical U, Tokyo, Nagoya U, Aichi,
Abstract
ASSOCIATION BETWEEN TREATMENT GOAL ACHIEVEMENT AND GRIT PERSONALITY CHARACTERISTICS OF ATTENDING PHYSICIAN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER CROSS-SECTIONAL STUDYOrg: Kochi Medical School, Okayama University Graduate School of Medicine, Showa University School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Yokohama City University Graduate School of Medicine, Yokohama-Shi Kanazawa-Ku, KANAGAWA-KEN, Japan,
Abstract
BASELINE IL-10 LEVELS AS A PREDICTIVE BIOMARKER FOR ACHIEVING CLINICAL RESPONSE WITH ABATACEPT IN ACPA+ PATIENTS WITH EARLY RAOrg: Bristol Myers Squibb, Parexel International GmbH, University of Leeds and Leeds NIHR Biomedical Research Centre, University of Occupational and Environmental Health, Kitakyushu, Japan, Hospital for Special Surgery,
Abstract
BASELINE PARAMETERS IDENTIFIED IN EARLY, METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS WITH BETTER OUTCOMES WITH CERTOLIZUMAB PEGOL+METHOTREXATE COMPARED TO PLACEBO+METHOTREXATE: POST-HOC ANALYSES OF C-OPERA, A RANDOMIZED, CONTROLLED, PHASE 3 SOrg: Hokkaido University Graduate School of Medicine, Hokkaido, The University of Tokyo, Tokyo, Japan, Keio University School of Medicine, Tokyo Women's Medical University, Tokyo, Japan, Nagoya University, Nagoya,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDYOrg: UCB Pharma, ASST Gaetano Pini-CTO, Dept of Rheumatology, Milan, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development, Centre for Therapeutic Innovation, University of Bath,
Abstract
BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDYOrg: UCB Pharma, Brigham and Women's Hospital/Massachusetts General Hospital, University of Glasgow, University of Oxford, Oxford University Hospitals NHS Trust,
Abstract
ASSOCIATIONS BETWEEN ORGAN INVOLVEMENTS AND GENDER, ALLERGY, AND MALIGNANCY IN 166 PATIENTS WITH IGG4-RELATED DISEASEOrg: Kyoto University Graduate School of Medicine, Kobe University Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Kobe, Japan, Kansai Electric Power Hospital, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Kansai Medical University Hospital,
Abstract
BETTER CLINICAL RESPONSES SEEN EARLY WITH THE LOADING DOSE OF CERTOLIZUMAB PEGOL ARE MAINTAINED UNTIL ONE YEAR Org: Keio University School of Medicine, University of Tokyo, Tokyo Women's Medical University, Tokyo, Japan, Nagoya University, Nagoya, University of Occupational and Environmental Health, Kitakyushu, Japan,